Hong Kong IPO Analytics - Regular Cornerstone Investors and Track Record
At the beginning of this year, we at Aequitas Research, wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...
659 Views
Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End
Shanghai Henlius Biotech (2696 HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...
516 Views
Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In our previous insights covering Shanghai Henlius, we have...
567 Views
Shanghai Henlius Biotech IPO Initiation: Going Large
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
648 Views
CStone Pharma's (基石药业) Lock-Up Expiry - Analysis of Potential Selling Shareholders
Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th. As we expect roughly USD 1 billion...
474 Views